Champions Oncology to Present at the 3rd annual Disruptive Growth & Healthcare Conference on May 9th

Thursday, May 3, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

HACKENSACK, N.J., May 3, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced

technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Wednesday, May 9th
at 8:40am. The conference is being hosted by RHK Capital and ReedSmith LLP, at Reed Smith's offices located at 599 Lexington Avenue.

The 2018 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.

About RHK Capital

Advisory Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK Capital is a boutique investment banking firm specializing in small to medium-sized transactions. RHK is led by a management team with extensive financial industry experience and a desire to provide companies and individuals with the tools and expertise to accomplish their financial goals. In addition to investment banking, RHK has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages, and business lending. As a division of Advisory Group Equity Services (AGES), all securities are offered through Advisory Group Equity Services Ltd., a registered broker-dealer, member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.

For those interested in attending, please visit www.DisruptNYC.com for more information.

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.

Cision View original content:http://www.prnewswire.com/news-releases/champions-oncology-to-present-at-the-3rd-annual-disruptive-growth--healthcare-conference-on-may-9th-300641528.html

SOURCE Champions Oncology, Inc.

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store